
In part 3 of this interview, Michael Mina, MD, PhD, discusses VYD2311’s variant-resistant design and the role pharmacists may play in explaining emerging immunization options.

In part 3 of this interview, Michael Mina, MD, PhD, discusses VYD2311’s variant-resistant design and the role pharmacists may play in explaining emerging immunization options.

In part 2 of this interview, Michael Mina, MD, PhD, discusses LIBERTY study data showing that VYD2311 boosted neutralizing activity without interfering with mRNA COVID-19 vaccine response.

Michael Mina, MD, PhD, discusses phase 3 LIBERTY study data showing that the monoclonal antibody VYD2311, alone or combined with an mRNA COVID-19 vaccine, was associated with fewer adverse events than vaccination alone.